Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

60 Degrees Pharmaceuticals (SXTP) Net Income towards Common Stockholders (2022 - 2025)

Historic Net Income towards Common Stockholders for 60 Degrees Pharmaceuticals (SXTP) over the last 4 years, with Q3 2025 value amounting to -$2.3 million.

  • 60 Degrees Pharmaceuticals' Net Income towards Common Stockholders fell 198.43% to -$2.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$8.2 million, marking a year-over-year increase of 110.14%. This contributed to the annual value of -$8.4 million for FY2024, which is 11481.37% down from last year.
  • According to the latest figures from Q3 2025, 60 Degrees Pharmaceuticals' Net Income towards Common Stockholders is -$2.3 million, which was down 198.43% from -$1.7 million recorded in Q2 2025.
  • In the past 5 years, 60 Degrees Pharmaceuticals' Net Income towards Common Stockholders registered a high of $4.1 million during Q3 2023, and its lowest value of -$4.3 million during Q2 2024.
  • In the last 4 years, 60 Degrees Pharmaceuticals' Net Income towards Common Stockholders had a median value of -$2.1 million in 2022 and averaged -$1.7 million.
  • Its Net Income towards Common Stockholders has fluctuated over the past 5 years, first soared by 38148.42% in 2023, then tumbled by 74938.24% in 2025.
  • Over the past 4 years, 60 Degrees Pharmaceuticals' Net Income towards Common Stockholders (Quarter) stood at -$1.7 million in 2022, then decreased by 25.37% to -$2.1 million in 2023, then dropped by 4.93% to -$2.2 million in 2024, then decreased by 6.3% to -$2.3 million in 2025.
  • Its Net Income towards Common Stockholders was -$2.3 million in Q3 2025, compared to -$1.7 million in Q2 2025 and -$2.0 million in Q1 2025.